We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone-Powered Microfluidic ‘Lab on a Strip’ Dengue Test More Powerful Than LFT Testing

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: Dengue test shows new hope for low-cost diagnostics (Photo courtesy of University of Reading)
Image: Dengue test shows new hope for low-cost diagnostics (Photo courtesy of University of Reading)

Dengue fever affects an estimated 400 million people each year. While most cases are mild, dengue infections can lead to significant complications and can be fatal. Dengue can be most severe in children and is a serious health challenge facing half the global population. Now, new ‘lab on a strip’ technology has shown the capability of smartphone-powered tests for dengue fever.

Biomedical technology researchers from the University of Reading (London, UK) have developed the new diagnostic test for research that uses ‘lab on a strip’ technology, which performs 10 or more tests a very small amount of liquid sample (such as blood, urine or saliva). The researchers used a new diagnostic kit called Cygnus to detect dengue fever with significantly improved rates over lateral flow testing kits.

The team trialled the tests alongside already established alternatives and found the new tests showed 82% clinical sensitivity, beating lateral flow testing (74% sensitivity) and matching hospital-based lab diagnostics (83% sensitivity). At the same time, these devices make 10 measurements allowing us to identify which of the four different dengue virus types caused the infection.

“The paper shows exciting potential for the use of the microfluidic ‘lab on a strip’ tests that can be used in conjunction with a smartphone and are more powerful than LFT testing in this case,” said Dr. Sarah Needs, Postdoctoral Research Associate in Microfluidic Antimicrobial Resistance Testing from the University of Reading. “As well as being cheap to produce, the lab on a strip technology allows users to test many different targets at once in one single sample, so it could be useful to detect multiple diseases not just one.”

“While some people might only recently learned of the trade-offs between home vs. lab testing following COVID-19, in many parts of the world rapid lateral flow tests are used for a range of illnesses including dengue,” added Dr. Alexander Edwards, Associate Professor in Biomedical Technology at the University of Reading co-created the lab on a strip technology. “With the Cygnus concept, we are tackling the biggest hurdle for home testing. How do you make something portable that can be cheaply mass produced while still matching laboratory test performance? By designing the microfluidic lab on a strip using mass-production melt-extrusion it is possible to scale up production and produce hundreds of thousands of tests. By recording results with smartphones, which are becoming ubiquitous, we have designed something that could be revolutionary for healthcare.”

Related Links:
University of Reading 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.